Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP Announces Exclusive Distribution Agreement with Leading Italian Medical Device Distributor AB Medica
Partnership further extends the availability of EDAP’s High Intensity Focused Ultrasound (HIFU) technology to one of the largest markets in Europe Complementary to AB Medica’s extensive product portfolio which includes robotic surgery solutions as well as ExactVu LYON, France , November 17, 2020 --
View HTML
Toggle Summary EDAP Announces Presentation at the Jefferies Virtual London Healthcare Conference
LYON , France, November 10, 2020 --  EDAP TMS SA  (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the Jefferies Virtual London Healthcare Conference , which is being held November 17-19, 2020.  Presentation Details
View HTML
Toggle Summary EDAP TMS SA to Announce Third Quarter 2020 Financial Results on November 18, 2020
Company to host conference call and webcast on Thursday, November 19 at 8:30 am EDT LYON, France , November 9, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter ended September 30, 2020
View HTML
Toggle Summary EDAP Hosting Key Opinion Leader Call on Focal One® and ExactVu™
Call to be Held Tuesday, September 22 nd @ 8am Eastern Time LYON, France , September 15, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will host a key opinion leader (KOL) call on its two lead commercial products, Focal One ® and
View HTML
Toggle Summary EDAP Announces Presentation at the HC Wainwright Virtual 22nd Annual Global Investment Conference
LYON, France , September 9, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that management will be presenting at the HC Wainwright Virtual 22nd Annual Global Investment Conference , which is being held September 14-15, 2020 .  Presentation
View HTML
Toggle Summary EDAP Announces First Patients Treated in Phase 2 Study of Focal One for the Treatment of Deep Invasive Endometriosis
       ·  First patients already treated as recruitment accelerates LYON, France , September 3, 2020 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first two patients have been treated in the company’s Phase 2 clinical trial assessing
View HTML
Toggle Summary EDAP Reports Second Quarter 2020 Results and Provides Operational Update
Completed multiple Focal One sales to renowned U.S. and international health care institutions, including multiple Focal One™-ExactVu™ bundled sales Announced first two U.S. publications in Journal of Urology detailing positive outcomes from U.S. studies of HIFU for the successful partial-gland
View HTML
Toggle Summary EDAP Announces Approval for Phase II Study Evaluating High Intensity Focused Ultrasound (HIFU) for Deep Invasive Endometriosis
Multicenter study to commence in September in France Reinforces company’s recent shift in strategic focus toward development of additional high-value HIFU tissue ablation indications LYON, France , August 25, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic
View HTML
Toggle Summary EDAP TMS SA to Announce Second Quarter 2020 Financial Results on August 26, 2020
Company to host conference call and webcast on Thursday, August 27 at 8:30 am EDT LYON, France , August 19, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the second quarter ended June 30, 2020 after the
View HTML
Toggle Summary EDAP Announces Two Publications Highlighting Favorable HIFU Focal Therapy Outcomes in Journal of Urology
  Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015.
View HTML